Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMPH NASDAQ:HROW NASDAQ:RCKT NASDAQ:SDGR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMPHAmphastar Pharmaceuticals$27.27-2.8%$25.76$20.39▼$53.96$1.27B0.8562,181 shs422,795 shsHROWHarrow$42.82+8.6%$36.12$20.85▼$59.23$1.58B0.33485,412 shs1.29 million shsRCKTRocket Pharmaceuticals$3.22+1.9%$3.16$2.19▼$22.01$347.44M0.623.61 million shs2.30 million shsSDGRSchrodinger$18.46-0.6%$20.22$16.60▼$28.47$1.36B1.791.15 million shs802,398 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMPHAmphastar Pharmaceuticals0.00%-4.62%-5.93%+8.01%-41.65%HROWHarrow0.00%+6.57%+1.55%+24.98%-12.67%RCKTRocket Pharmaceuticals0.00%-3.66%+3.61%+9.72%-83.92%SDGRSchrodinger0.00%-2.93%-4.18%-12.41%-10.42%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMPHAmphastar Pharmaceuticals$27.27-2.8%$25.76$20.39▼$53.96$1.27B0.8562,181 shs422,795 shsHROWHarrow$42.82+8.6%$36.12$20.85▼$59.23$1.58B0.33485,412 shs1.29 million shsRCKTRocket Pharmaceuticals$3.22+1.9%$3.16$2.19▼$22.01$347.44M0.623.61 million shs2.30 million shsSDGRSchrodinger$18.46-0.6%$20.22$16.60▼$28.47$1.36B1.791.15 million shs802,398 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMPHAmphastar Pharmaceuticals0.00%-4.62%-5.93%+8.01%-41.65%HROWHarrow0.00%+6.57%+1.55%+24.98%-12.67%RCKTRocket Pharmaceuticals0.00%-3.66%+3.61%+9.72%-83.92%SDGRSchrodinger0.00%-2.93%-4.18%-12.41%-10.42%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMPHAmphastar Pharmaceuticals 2.40Hold$31.6015.88% UpsideHROWHarrow 3.13Buy$64.6751.02% UpsideRCKTRocket Pharmaceuticals 2.41Hold$16.73419.67% UpsideSDGRSchrodinger 2.67Moderate Buy$27.8350.78% UpsideCurrent Analyst Ratings BreakdownLatest RCKT, SDGR, HROW, and AMPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/26/2025AMPHAmphastar PharmaceuticalsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$28.00 ➝ $32.008/20/2025RCKTRocket PharmaceuticalsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$4.00 ➝ $10.008/20/2025RCKTRocket PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.008/18/2025SDGRSchrodingerMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$28.00 ➝ $19.008/15/2025SDGRSchrodingerCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$35.00 ➝ $20.008/14/2025SDGRSchrodingerBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$25.008/14/2025HROWHarrowZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy8/14/2025HROWHarrowBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$62.00 ➝ $63.008/14/2025SDGRSchrodingerBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$25.008/13/2025HROWHarrowHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$60.00 ➝ $64.008/12/2025AMPHAmphastar PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$36.00(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMPHAmphastar Pharmaceuticals$731.97M1.73$4.86 per share5.61$15.23 per share1.79HROWHarrow$199.61M7.94$0.15 per share288.28$1.95 per share21.96RCKTRocket PharmaceuticalsN/AN/AN/AN/A$5.08 per shareN/ASDGRSchrodinger$207.54M6.55N/AN/A$5.78 per share3.19Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMPHAmphastar Pharmaceuticals$159.52M$2.6710.218.29N/A18.64%20.76%9.68%11/5/2025 (Estimated)HROWHarrow-$17.48M-$0.25N/A107.05N/A-4.49%-2.18%-0.35%11/12/2025 (Estimated)RCKTRocket Pharmaceuticals-$258.75M-$2.51N/AN/AN/AN/A-65.11%-55.99%11/6/2025 (Estimated)SDGRSchrodinger-$187.12M-$2.48N/AN/AN/A-76.22%-45.70%-24.81%11/11/2025 (Estimated)Latest RCKT, SDGR, HROW, and AMPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025HROWHarrow$0.01$0.24+$0.23$0.13$64.23 million$63.74 million8/7/2025Q2 2025RCKTRocket Pharmaceuticals-$0.57-$0.59-$0.02-$0.62$4.36 millionN/A8/6/2025Q2 2025SDGRSchrodinger-$0.83-$0.59+$0.24-$0.59$52.03 million$54.76 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMPHAmphastar PharmaceuticalsN/AN/AN/AN/AN/AHROWHarrowN/AN/AN/AN/AN/ARCKTRocket PharmaceuticalsN/AN/AN/AN/AN/ASDGRSchrodingerN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMPHAmphastar Pharmaceuticals0.803.292.21HROWHarrow0.780.620.58RCKTRocket Pharmaceuticals0.056.396.39SDGRSchrodingerN/A3.303.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMPHAmphastar Pharmaceuticals65.09%HROWHarrow72.76%RCKTRocket Pharmaceuticals98.39%SDGRSchrodinger79.05%Insider OwnershipCompanyInsider OwnershipAMPHAmphastar Pharmaceuticals27.10%HROWHarrow13.67%RCKTRocket Pharmaceuticals24.76%SDGRSchrodinger21.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMPHAmphastar Pharmaceuticals2,02846.49 million33.90 millionOptionableHROWHarrow18037.00 million31.94 millionOptionableRCKTRocket Pharmaceuticals240107.90 million81.19 millionOptionableSDGRSchrodinger79073.61 million58.15 millionOptionableRCKT, SDGR, HROW, and AMPH HeadlinesRecent News About These CompaniesUBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Buys 2,737,728 Shares of Schrodinger, Inc. $SDGRSeptember 15 at 3:09 AM | marketbeat.comGeneos Wealth Management Inc. Boosts Position in Schrodinger, Inc. $SDGRSeptember 14 at 4:56 AM | marketbeat.comSchrodinger (NASDAQ:SDGR) Stock Price Down 5.9% - Should You Sell?September 12 at 5:29 PM | marketbeat.comJones Financial Companies Lllp Increases Stock Position in Schrodinger, Inc. $SDGRSeptember 12 at 5:11 AM | marketbeat.comSchrödinger (SDGR): Evaluating Valuation as Market Sentiment Remains QuietSeptember 11, 2025 | finance.yahoo.comSchrodinger, Inc. (NASDAQ:SDGR) Given Consensus Recommendation of "Moderate Buy" by AnalystsSeptember 10, 2025 | marketbeat.comDoes Schrodinger (SDGR) Have the Potential to Rally 40.43% as Wall Street Analysts Expect?September 9, 2025 | zacks.comSchrödinger, Inc. (SDGR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 8, 2025 | seekingalpha.comSchrodinger Announces CFO Geoffrey Porges’ DepartureSeptember 8, 2025 | msn.comParkman Healthcare Partners LLC Reduces Holdings in Schrodinger, Inc. $SDGRSeptember 8, 2025 | marketbeat.comSchrodinger, Inc. $SDGR Shares Sold by Northern Trust CorpSeptember 7, 2025 | marketbeat.comRussell Investments Group Ltd. Reduces Stock Position in Schrodinger, Inc. $SDGRSeptember 2, 2025 | marketbeat.comKodai Capital Management LP Makes New $3.03 Million Investment in Schrodinger, Inc. $SDGRSeptember 1, 2025 | marketbeat.comSchrodinger (NASDAQ:SDGR) Downgraded to "Sell" Rating by Wall Street ZenSeptember 1, 2025 | marketbeat.comTema Etfs LLC Sells 18,331 Shares of Schrodinger, Inc. $SDGRAugust 31, 2025 | marketbeat.comNuveen LLC Makes New $2.87 Million Investment in Schrodinger, Inc. $SDGRAugust 31, 2025 | marketbeat.comAlphaQuest LLC Trims Holdings in Schrodinger, Inc. $SDGRAugust 29, 2025 | marketbeat.comDeutsche Bank AG Sells 188,717 Shares of Schrodinger, Inc. $SDGRAugust 27, 2025 | marketbeat.comAmerican Century Companies Inc. Invests $19.79 Million in Schrodinger, Inc. $SDGRAugust 26, 2025 | marketbeat.comSchrodinger, Inc. $SDGR Shares Sold by Vanguard Group Inc.August 24, 2025 | marketbeat.comSchrödinger: A Complex Story With Many Moving PartsAugust 21, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRCKT, SDGR, HROW, and AMPH Company DescriptionsAmphastar Pharmaceuticals NASDAQ:AMPH$27.27 -0.79 (-2.82%) Closing price 04:00 PM EasternExtended Trading$27.28 +0.02 (+0.06%) As of 04:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.Harrow NASDAQ:HROW$42.82 +3.40 (+8.63%) Closing price 04:00 PM EasternExtended Trading$43.45 +0.63 (+1.47%) As of 05:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.Rocket Pharmaceuticals NASDAQ:RCKT$3.22 +0.06 (+1.90%) Closing price 04:00 PM EasternExtended Trading$3.17 -0.05 (-1.68%) As of 06:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.Schrodinger NASDAQ:SDGR$18.46 -0.11 (-0.59%) Closing price 04:00 PM EasternExtended Trading$18.44 -0.02 (-0.08%) As of 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Royal Caribbean's 33% Dividend Hike Signals Deeper Growth MarketBeat Week in Review – 09/08 - 09/12 Adobe’s Rebound Has Room to Run: 25% Upside by Year-End Wall Street Eyes +30% Upside in Synopsys After Huge Earnings Fall Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
